{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:53:53Z","timestamp":1787068433235,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is the standard of care for locally advanced oesophagogastric adenocarcinoma (LA-OGA) in Western countries. However, completing treatment is challenging for patients, particularly in the postoperative setting. This study investigated the impact of adjuvant chemotherapy (ACT) administration and treatment completion on survival outcomes in patients receiving FLOT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Charts of LA-OGA patients treated from 2017 to 2023 were retrospectively reviewed. Survival was analysed using Kaplan\u2013Meier and restricted mean survival time (RMST) analyses, with propensity score matching (PSM) adjustments. Subgroup analyses were stratified by pathological nodal status and tumour regression grade (Mandard TRG). The primary endpoint was 3-year overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 233 patients, among whom 62.4% completed the full perioperative FLOT regimen and 21% did not receive ACT. After PSM adjustment, 3-year OS for patients who completed and those who did not complete perioperative therapy was 69% and 57%, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.09). The 3-year OS was 81% and 52% for patients who did and did not receive ACT, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). In multivariate analysis, completion of perioperative FLOT was independently associated with improved OS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). Survival improvement with ACT was observed in the ypN-positive subgroup but not in the ypN-negative subgroup.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Perioperative FLOT administration is recommended as the standard of care for LA-OGA. The survival impact of ACT might be influenced by pathological lymph node metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10120-025-01643-5","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:59:35Z","timestamp":1752505175000},"page":"968-981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma"],"prefix":"10.1007","volume":"28","author":[{"given":"Keiji","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacheen","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Chaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naureen","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Fribbens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0286-8703","authenticated-orcid":false,"given":"Ian","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"1643_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"1643_CR2","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon J-P, Conroy T, Bouch\u00e9 O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715\u201321.","journal-title":"J Clin Oncol"},{"key":"1643_CR3","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"S-E Al-Batran","year":"2019","unstructured":"Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357.","journal-title":"Lancet"},{"key":"1643_CR4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: Interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296\u2013304.","journal-title":"J Clin Oncol"},{"key":"1643_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"Y-J Bang","year":"2012","unstructured":"Bang Y-J, Kim Y-W, Yang H-K, Chung HC, Park Y-K, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315\u201321.","journal-title":"Lancet"},{"key":"1643_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s10120-023-01419-9","volume":"26","author":"Y Kodera","year":"2023","unstructured":"Kodera Y, Yoshida K, Kochi M, Sano T, Ichikawa W, Kakeji Y, et al. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study. Gastric Cancer. 2023;26:1063\u20138.","journal-title":"Gastric Cancer"},{"key":"1643_CR7","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320.","journal-title":"N Engl J Med"},{"key":"1643_CR8","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"Y-K Kang","year":"2021","unstructured":"Kang Y-K, Yook JH, Park Y-K, Lee JS, Kim Y-W, Kim JY, et al. PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903\u201313.","journal-title":"J Clin Oncol"},{"key":"1643_CR9","doi-asserted-by":"crossref","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial. Lancet Oncol [Internet]. 2025;26(3):312\u20139 [cited 12 Feb 2025]. http:\/\/www.thelancet.com\/article\/S1470204524006764\/abstract.","DOI":"10.1016\/S1470-2045(24)00676-4"},{"key":"1643_CR10","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1245\/s10434-020-09045-w","volume":"28","author":"JA Drake","year":"2021","unstructured":"Drake JA, Stiles ZE, Tsao MW, Deneve JL, Glazer ES, Yakoub D, et al. Analysis of the survival impact of postoperative chemotherapy after preoperative chemotherapy and resection for gastric cancer. Ann Surg Oncol. 2021;28:1417\u201327.","journal-title":"Ann Surg Oncol"},{"key":"1643_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/bjs\/znab427","volume":"109","author":"S Rahman","year":"2022","unstructured":"Rahman S, Thomas B, Maynard N, Park MH, Wahedally M, Trudgill N, et al. Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery. Br J Surg. 2022;109:227\u201336.","journal-title":"Br J Surg"},{"key":"1643_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.35340","volume":"4","author":"L Deng","year":"2021","unstructured":"Deng L, Groman A, Jiang C, Perimbeti S, Gabriel E, Kukar M, et al. Association of preoperative chemosensitivity with postoperative survival in patients with resected gastric adenocarcinoma. JAMA Netw Open. 2021;4: e2135340.","journal-title":"JAMA Netw Open"},{"key":"1643_CR13","unstructured":"SPACE-FLOT Investigators. Pathological response guides adjuvant 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in surgically resected gastro-oesophageal cancer (SPACE-FLOT): international cohort study. Br J Surg. 2025;112:znaf056."},{"key":"1643_CR14","first-page":"2680","volume":"73","author":"AM Mandard","year":"1994","unstructured":"Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathol Correlat Cancer. 1994;73:2680\u20136.","journal-title":"Clinicopathol Correlat Cancer"},{"key":"1643_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","volume":"18","author":"D Cunningham","year":"2017","unstructured":"Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2\u20133 trial. Lancet Oncol. 2017;18:357\u201370.","journal-title":"Lancet Oncol"},{"key":"1643_CR16","doi-asserted-by":"crossref","unstructured":"Capovilla G, Pierobon ES, Moletta L, Scarton A, Sciuto ME, Tagkalos E, et al. Prognostic value of tumor regression grade after chemotherapy versus chemoradiotherapy in patients undergoing neoadjuvant treatment for locally advanced esophageal adenocarcinoma. Ann Surg Oncol. 2025;1\u201310.","DOI":"10.1245\/s10434-025-17468-6"},{"key":"1643_CR17","doi-asserted-by":"crossref","unstructured":"Heckl SM, Behrens H-M, Ebert U, Ulase D, Richter F, Becker T, et al. Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world. Gastric Cancer. 2025;1\u201311.","DOI":"10.1007\/s10120-025-01624-8"},{"key":"1643_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.humpath.2020.11.001","volume":"108","author":"G Saliba","year":"2021","unstructured":"Saliba G, Detlefsen S, Carneiro F, Conner J, Dorer R, Fl\u00e9jou JF, et al. Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey. Hum Pathol. 2021;108:60\u20137.","journal-title":"Hum Pathol"},{"key":"1643_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11605-019-04462-z","volume":"24","author":"MFKP Ramos","year":"2020","unstructured":"Ramos MFKP, de Castria TB, Pereira MA, Dias AR, Antonacio FF, Zilberstein B, et al. Return to intended oncologic treatment (RIOT) in resected gastric cancer patients. J Gastrointest Surg. 2020;24:19\u201327.","journal-title":"J Gastrointest Surg"},{"key":"1643_CR20","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00423-022-02515-7","volume":"407","author":"M Garcia-Nebreda","year":"2022","unstructured":"Garcia-Nebreda M, Zorrilla-Vaca A, Ripoll\u00e9s-Melchor J, Abad-Motos A, Alvaro Cifuentes E, Abad-Gurumeta A, et al. Early return to intended oncologic therapy after implementation of an enhanced recovery after surgery pathway for gastric cancer surgery. Langenbecks Arch Surg. 2022;407:2293\u2013300.","journal-title":"Langenbecks Arch Surg"},{"key":"1643_CR21","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1470-2045(17)30447-3","volume":"18","author":"D Alderson","year":"2017","unstructured":"Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1249\u201360.","journal-title":"Lancet Oncol"},{"key":"1643_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.5557","volume":"5","author":"J-X Lin","year":"2022","unstructured":"Lin J-X, Tang Y-H, Lin G-J, Ma Y-B, Desiderio J, Li P, et al. Association of adjuvant chemotherapy with overall survival among patients with locally advanced gastric cancer after neoadjuvant chemotherapy. JAMA Netw Open. 2022;5: e225557.","journal-title":"JAMA Netw Open"},{"key":"1643_CR23","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.3390\/curroncol29030161","volume":"29","author":"A Ballhausen","year":"2022","unstructured":"Ballhausen A, Bartels P, Iacovella I, Hoegner A, Lorusso A, Bichev D, et al. Impact of postoperative chemotherapy in patients with gastric\/gastroesophageal adenocarcinoma treated with perioperative chemotherapy. Curr Oncol. 2022;29:1983\u201396.","journal-title":"Curr Oncol"},{"key":"1643_CR24","doi-asserted-by":"crossref","unstructured":"Lordick F, Mauer ME, Stocker G, Cella CA, Ben-Aharon I, Piessen G, et al. Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and\/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study. Ann Oncol [Internet]. 2024;36(2):197\u2013207 [cited 14 Nov 2024]. http:\/\/www.annalsofoncology.org\/article\/S0923753424049068\/abstract.","DOI":"10.1016\/j.annonc.2024.10.829"},{"key":"1643_CR25","volume":"2013","author":"A Mirza","year":"2013","unstructured":"Mirza A, Pritchard S, Welch I. The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas. Int J Surg Oncol. 2013;2013: 781742.","journal-title":"Int J Surg Oncol"},{"key":"1643_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.amjsurg.2014.12.036","volume":"210","author":"G Luc","year":"2015","unstructured":"Luc G, Gersen-Cherdieu H, Degrandi O, Terrebonne E, Chiche L, Collet D. Impact of postoperative chemotherapy in patients with locally advanced gastroesophageal adenocarcinoma treated with perioperative chemotherapy strategy. Am J Surg. 2015;210:15\u201323.","journal-title":"Am J Surg"},{"key":"1643_CR27","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1186\/s12885-016-2708-0","volume":"16","author":"S Lichthardt","year":"2016","unstructured":"Lichthardt S, Kerscher A, Dietz UA, Jurowich C, Kunzmann V, von Rahden BHA, et al. Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer. BMC Cancer. 2016;16:650.","journal-title":"BMC Cancer"},{"key":"1643_CR28","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1007\/s11605-017-3594-8","volume":"21","author":"G Karagkounis","year":"2017","unstructured":"Karagkounis G, Squires MH 3rd, Melis M, Poultsides GA, Worhunsky D, Jin LX, et al. Predictors and prognostic implications of perioperative chemotherapy completion in gastric cancer. J Gastrointest Surg. 2017;21:1984\u201392.","journal-title":"J Gastrointest Surg"},{"key":"1643_CR29","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/j.ejso.2019.03.040","volume":"45","author":"M van Putten","year":"2019","unstructured":"van Putten M, Lemmens VEPP, van Laarhoven HWM, Pruijt HFM, Nieuwenhuijzen GAP, Verhoeven RHA. Poor compliance with perioperative chemotherapy for resectable gastric cancer and its impact on survival. Eur J Surg Oncol. 2019;45:1926\u201333.","journal-title":"Eur J Surg Oncol"},{"key":"1643_CR30","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1245\/s10434-019-07454-0","volume":"26","author":"FJF Coimbra","year":"2019","unstructured":"Coimbra FJF, de Jesus VHF, Ribeiro HSC, Diniz AL, de Godoy AL, de Farias IC, et al. Impact of ypT, ypN, and adjuvant therapy on survival in gastric cancer patients treated with perioperative chemotherapy and radical surgery. Ann Surg Oncol. 2019;26:3618\u201326.","journal-title":"Ann Surg Oncol"},{"key":"1643_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.suronc.2017.06.001","volume":"33","author":"L Sisic","year":"2020","unstructured":"Sisic L, Blank S, Nienh\u00fcser H, Haag GM, J\u00e4ger D, Bruckner T, et al. The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma. Surg Oncol. 2020;33:177\u201388.","journal-title":"Surg Oncol"},{"key":"1643_CR32","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s11605-018-04087-8","volume":"23","author":"G Papaxoinis","year":"2019","unstructured":"Papaxoinis G, Kamposioras K, Weaver JMJ, Kordatou Z, Stamatopoulou S, Germetaki T, et al. The role of continuing perioperative chemotherapy post surgery in patients with esophageal or gastroesophageal junction adenocarcinoma: a multicenter cohort study. J Gastrointest Surg. 2019;23:1729\u201341.","journal-title":"J Gastrointest Surg"},{"key":"1643_CR33","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1007\/s11912-024-01594-7","volume":"26","author":"NA Cortes-Mejia","year":"2024","unstructured":"Cortes-Mejia NA, Lillemoe HA, Cata JP. Return to intended oncological therapy: state of the art and perspectives. Curr Oncol Rep. 2024;26:1420\u201330.","journal-title":"Curr Oncol Rep"},{"key":"1643_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1245\/s10434-024-16440-0","volume":"32","author":"A Koo","year":"2025","unstructured":"Koo A, Mavani PT, Sok C, Goyal S, Concors S, Mason MC, et al. Effect of minimally invasive gastrectomy on return to intended oncologic therapy for gastric cancer. Ann Surg Oncol. 2025;32:230\u20139.","journal-title":"Ann Surg Oncol"},{"key":"1643_CR35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/jso.24601","volume":"115","author":"JH Saunders","year":"2017","unstructured":"Saunders JH, Bowman CR, Reece-Smith AM, Pang V, Dorrington MS, Mumtaz E, et al. The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. J Surg Oncol. 2017;115:821\u20139.","journal-title":"J Surg Oncol"},{"key":"1643_CR36","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.ejso.2015.07.010","volume":"41","author":"T Glatz","year":"2015","unstructured":"Glatz T, Bronsert P, Sch\u00e4fer M, Kulemann B, Marjanovic G, Sick O, et al. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: postoperative chemotherapy has a substantial impact on outcome. Eur J Surg Oncol. 2015;41:1300\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"1643_CR37","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41416-023-02217-x","volume":"128","author":"A Athauda","year":"2023","unstructured":"Athauda A, Nankivell M, Langer R, Pritchard S, Langley RE, von Loga K, et al. Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials. Br J Cancer. 2023;128:2036\u201343.","journal-title":"Br J Cancer"},{"key":"1643_CR38","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1200\/JCO.2015.65.7692","volume":"34","author":"EC Smyth","year":"2016","unstructured":"Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AFC, Lampis A, et al. Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial. J Clin Oncol. 2016;34:2721\u20137.","journal-title":"J Clin Oncol"},{"key":"1643_CR39","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00420","volume":"6","author":"BM Huffman","year":"2022","unstructured":"Huffman BM, Aushev VN, Budde GL, Chao J, Dayyani F, Hanna D, et al. Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precis Oncol. 2022;6: e2200420.","journal-title":"JCO Precis Oncol"},{"key":"1643_CR40","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med. 2025;392:323\u201335.","journal-title":"N Engl J Med"},{"key":"1643_CR41","doi-asserted-by":"publisher","first-page":"7173","DOI":"10.1245\/s10434-021-09779-1","volume":"28","author":"Y Kubo","year":"2021","unstructured":"Kubo Y, Tanaka K, Yamasaki M, Yamashita K, Makino T, Saito T, et al. Influences of the Charlson Comorbidity Index and nutrition status on prognosis after esophageal cancer surgery. Ann Surg Oncol. 2021;28:7173\u201382.","journal-title":"Ann Surg Oncol"},{"key":"1643_CR42","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1245\/s10434-020-08762-6","volume":"28","author":"Y Kubo","year":"2021","unstructured":"Kubo Y, Miyata H, Sugimura K, Shinno N, Asukai K, Hasegawa S, et al. Prognostic implication of postoperative weight loss after esophagectomy for esophageal squamous cell cancer. Ann Surg Oncol. 2021;28:184\u201393.","journal-title":"Ann Surg Oncol"},{"key":"1643_CR43","doi-asserted-by":"publisher","unstructured":"Janjigian YY, Al-Batran S-E, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med [Internet]. 2025. https:\/\/doi.org\/10.1056\/nejmoa2503701","DOI":"10.1056\/nejmoa2503701"},{"key":"1643_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-023-02458-w","volume":"130","author":"HA Clements","year":"2024","unstructured":"Clements HA, Underwood TJ, Petty RD. Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma. Br J Cancer. 2024;130:9\u201318.","journal-title":"Br J Cancer"},{"key":"1643_CR45","doi-asserted-by":"publisher","first-page":"S890","DOI":"10.1016\/j.annonc.2024.08.1494","volume":"35","author":"HA Clements","year":"2024","unstructured":"Clements HA, Dobrzhanskiy O, Yang J, Bausys A, Ferri LE, Ku GY, et al. 1428P Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: an international cohort study. Ann Oncol. 2024;35:S890.","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1007\/s10120-025-01697-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000}}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01643-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01643-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01643-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T06:37:29Z","timestamp":1766212649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01643-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1643"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01643-5","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to amend references 30 to 45 and the in-text citation of supplementary material 6.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10120-025-01697-5","URL":"https:\/\/doi.org\/10.1007\/s10120-025-01697-5","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DC reports research funding from Clovis, Eli Lilly, 4SC, Leap, and Roche. IC reports the advisory boards for Bristol Myers Squibb, AstraZeneca, OncXerna, Astellas, GSK, Eisai, Daiichi-Sankyo, Taiho, Servier, Seagen, BioNTech, Novartis, Takeda, Elevation Oncology, Beigene, and Jazz Pharmaceuticals and has received research funding from Eli Lilly and Janssen-Cilag and honoraria from Eli Lilly, Eisai, Servier, Roche, BMS, Jazz Pharmaceuticals, Astellas, and Roche. NS reports serving on the advisory boards of AstraZeneca, MSD Oncology, Novartis, Guardant, GSK, Gilead, Seagen, Janssen, Takeda, Moderna, and BMS; research funding from AstraZeneca, BMS, Guardant, and Gilead; and honoraria from Merck, Novartis, Amgen, Eli Lilly, GSK, Servier, Pierre Fabre, Seagen, MSD Oncology, BMS, AstraZeneca, Astellas, and Guardant. SR receives financial support from Boehringer, Merck, Servier, and Bayer; has served on advisory boards for HOOKIPA, Bayer, Beigene, AstraZeneca, Merck, Seagen, and Servier. The remaining authors declare no conflicts of interest. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}